C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside

• Published in: Current neuropharmacology Vol. 19; no. 7; pp. 1038 - 1068
• Main Authors: Mylvaganam, Sivakami, Earnshaw, Rebecca, Heymann, Gregory, Kalia, Suneil K, Kalia, Lorraine V
• Format: Journal Article
• Language: English
• Published: United Arab Emirates Bentham Science Publishers Ltd 01-01-2021; Bentham Science Publishers
• Subjects: Cerebellar Ataxia; Humans; Huntington Disease; Mutation; Spinocerebellar Ataxias; Ubiquitin-Protein Ligases - genetics; neurodegenerative diseases; cerebellar ataxia; STUB1-associated disease; huntington disease; STUB1; polyglutamine diseases; Alzheimer's disease; amyotrophic lateral sclerosis; parkinson's disease
• ISSN: 1570-159X; 1875-6190
• DOI: 10.2174/1570159X18666201116145507

Neurodegenerative diseases are characterized by the increasing dysfunction and death of neurons, resulting in progressive impairment of a person’s mobility and/or cognition. Protein misfolding and aggregation are commonly hypothesized to cause neurotoxicity and, eventually, neuronal degeneration that are associated with these diseases. Emerging experimental evidence, as well as recent findings from human studies, reveal that the C-terminus of Hsp70 Interacting Protein (CHIP), or STIP1 Homology and U-box containing Protein 1 (STUB1), is a quality control protein involved in neurodegeneration. Here, we review evidence that CHIP interacts with and plays a role in regulating proteins implicated in the pathogenesis of Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and polyglutamine diseases, including Huntington’s disease and spinocerebellar ataxias. We also review clinical findings identifying mutations in STUB1 as a cause of both autosomal recessive and autosomal dominant forms of cerebellar ataxia. We propose that CHIP modulation may have therapeutic potential for the treatment of multiple neurodegenerative diseases.